Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

490

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Trastuzumab deruxtecan
DRUG: Ramucirumab
DRUG: Paclitaxel

Sponsor

Daiichi Sankyo

Collaborators

[object Object]